|Bid||0.0000 x 0|
|Ask||0.0000 x 0|
|Day's Range||0.0570 - 0.0660|
|52 Week Range||0.0110 - 0.0750|
|Beta (3Y Monthly)||1.49|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 8, 2019 - Nov 13, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||3.50|
KNOXVILLE, TN, Sept. 24, 2019 -- Provectus (OTCQB: PVCT) today announced that data from an ongoing clinical trial of lysosomal-targeting cancer immunotherapy PV-10® in.
Provectus (PVCT) today announced the addition of Dr. Harold Schmitz to the Company’s new Scientific Advisory Board. Provectus is a clinical-stage biotechnology company developing a new class of drugs for oncology and dermatology based on an entire, wholly-owned, family of small molecules called halogenated xanthenes.
Two-stage, 34-patient, Phase 2 study combines PV-10 and Keytruda® (pembrolizumab) for treatment of metastatic neuroendocrine tumorsCombination powered for 19% ORR vs 3.7% ORR.
Dr. Akers to assist Provectus develop and manage new Company scientific advisory board KNOXVILLE, TN, July 29, 2019 -- Provectus (OTCQB: PVCT) today announced the addition.
- Further patent protection of combinations of intratumoral PV-10 and checkpoint inhibitor (CI) drugs for the treatment of multiple, different, solid tumor cancers KNOXVILLE,.
Metastatic neuroendocrine tumors: Monotherapy data presentations planned. Phase 2 combination therapy trial designs with different classes of checkpoint inhibitor drugs being.
No safety concerns identified; no significant overlap of or unexpected toxicities65% overall ORR with 9% CR (RECIST 1.1) maintainedPreliminary PFS of 12.3 monthsChanges in T.
No safety concerns identified50% ORR and 83% disease control of injected lesionsStable Chromogranin A responses and quality of life scores for nearly all subjects KNOXVILLE,.
Provectus (PVCT) today announced the appointment of Bruce Horowitz as the Company’s Chief Operating Officer. Mr. Horowitz had previously served as Provectus’ Chief Operations Consultant since 2017. Provectus is a clinical-stage biotechnology company developing a new class of drugs for oncology and dermatology based on a wholly-owned family of chemical small molecules called halogenated xanthenes.
Metastatic neuroendocrine tumors; Advanced cutaneous melanomaIntratumoral administration of PV-10 to visceral and superficial disease locationsSingle-agent and combination.
Provectus (PVCT) today announced the appointment of Heather Raines as the Company’s Chief Financial Officer (CFO). Mrs. Raines had previously served as Provectus’ Controller since 2017, and now replaces the Company’s interim CFO. From 2007 to 2015, Mrs. Raines served as Controller of the Oak Ridge, Tennessee location of AMETEK, Inc. (AME), a global manufacturer of electronic instruments and electromechanical devices.
KNOXVILLE, TN, March 21, 2019 -- Provectus (OTCQB: PVCT) today provided updates on the Company's metastatic uveal melanoma drug development program for its lead.
KNOXVILLE, TN & NEW YORK, NY, Feb. 19, 2019 (GLOBE NEWSWIRE) -- Provectus (PVCT) and the Pediatric Oncology Experimental Therapeutics Investigators Consortium (POETIC), a group of 10 top-tier academic medical centers developing new pediatric cancer therapies, today announced that OncoTargets and Therapy (OTT) has published preclinical results from in vitro and animal tumor model studies on PV-10 for the treatment of neuroblastoma. This work was led by Dr. Aru Narendran and his team at the University of Calgary’s POETIC Preclinical and Drug Discovery Laboratory.
KNOXVILLE, TN, Feb. 12, 2019 -- Provectus (OTCQB: PVCT) today announced that orphan drug designation (ODD) status was granted by the U.S. Food and Drug Administration (FDA) to.
- 72 patients were treated with either ILI or PV-10 at Australia’s Princess Alexandra Hospital; data were prospectively recorded; primary outcome was melanoma-specific survival;.
Lesion-level response data from main cohort of advanced melanoma patients naïve to immune checkpoint inhibition in Phase 1b/2 combination study of PV-10 and KEYTRUDA®.
Provectus (PVCT) today provided an update on the Company’s small molecule clinical development program for its investigational immuno-dermatology drug PH-10 for the treatments of psoriasis and atopic dermatitis. Pathways significantly improved by PH-10 use include published psoriasis transcriptomes and cellular responses mediated by IL-17, IL-22, and interferons. The Company has finished two toxicology-focused, non-clinical, single administration studies using carbon-14- (14C-) labeled rose bengal disodium (RB) to demonstrate lack of systemic uptake.
Provectus (PVCT) today announced that Ed Pershing, CPA, the Chairman of the Company’s board of directors, was recognized by the Haslam College of Business (HCB) at the University of Tennessee, Knoxville as HCB’s 2018 Outstanding Entrepreneur. Mr. Pershing also is Chief Executive Officer and co-founder of 35-year-old, privately-held, healthcare management consulting and accounting firm PYA, P.C. Ed Pershing (HCB, ’74) grew up in Alcoa, Tennessee, surrounded by a supportive family.
KNOXVILLE, TN, Nov. 05, 2018 -- Provectus (OTCQB: PVCT) today announced that the Company was granted orphan drug designation (ODD) by the U.S. Food and Drug Administration.